ReviewClinics in perinatology2014
Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity.
Review in Clinics in perinatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Pooled it
- Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial.JAMA pediatrics · 2018Trial
- Analytical study of influence of polymorphisms of VEGF+936T/C, ACE ID, TNF308G/A, and GSTP1 genes on retinopathy of prematurity progression/regression.Indian journal of ophthalmology · 2026Article
- Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies.Antibodies (Basel, Switzerland) · 2024Review
- Review
- Editorial: Identification of novel biomarkers for retinopathy of prematurity in preterm infants by use of innovative technologies and artificial intelligence.Frontiers in pediatrics · 2024Article
- Primary and additional treatment preference in aggressive retinopathy of prematurity and type 1 retinopathy of prematurity.BMJ open ophthalmology · 2023Article
- New Aspects on the Treatment of Retinopathy of Prematurity: Currently Available Therapies and Emerging Novel Therapeutics.International journal of molecular sciences · 2022Review
- Neurosensory Alterations in Retinopathy of Prematurity: A Window to Neurological Impairments Associated to Preterm Birth.Biomedicines · 2022Review
- Treatment for Nontype 1 Retinopathy of Prematurity by Intravitreal Injection of Antivascular Endothelial Growth Factor Drugs.Journal of ophthalmology · 2022Article
- Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity.International journal of retina and vitreous · 2021Article
- Hypertension in neonates treated with intravitreal bevacizumab for retinopathy of prematurity.Journal of perinatology : official journal of the California Perinatal Association · 2021Article
- A 60% Edible Ethanolic Extract ofMolecules (Basel, Switzerland) · 2021Article
- Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors.International journal of retina and vitreous · 2021Article
- Vascular Endothelial Growth Factor Signaling in Models of Oxygen-Induced Retinopathy: Insights Into Mechanisms of Pathology in Retinopathy of Prematurity.Frontiers in pediatrics · 2021Review
- Bumetanide Suppression of Angiogenesis in a Rat Model of Oxygen-Induced Retinopathy.International journal of molecular sciences · 2020Article
- Enhancing Retinal Endothelial Glycolysis by Inhibiting UCP2 Promotes Physiologic Retinal Vascular Development in a Model of Retinopathy of Prematurity.Investigative ophthalmology & visual science · 2019Article
- Discovering Mechanisms in the Changing and Diverse Pathology of Retinopathy of Prematurity: The Weisenfeld Award Lecture.Investigative ophthalmology & visual science · 2019Article
- Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2019Article
- Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes.Korean journal of ophthalmology : KJO · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
In this article, the growing problem of retinopathy of prematurity (ROP) worldwide, treatments for severe ROP including standard-of-care laser treatment, and the need for new treatments are discussed. Also discussed are the reasons to consider inhibiting the vascular endothelial growth factor (VEGF) signaling pathway in severe ROP and the concerns about broad VEGF inhibition. Finally, the potential role of VEGF in ROP based on studies in animal models of oxygen-induced retinopathy, the effects of anti-VEGF based on basic research data, and the clinical relevance of these data are covered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.